Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer

Annals of Internal Medicine

Volumn 138, Issue 2, 2003, Pages 90-97

  Du, Xianglin L ^a,b,c   Key, Charles R ^a,b   Osborne, Cynthia ^a,b   Mahnken, Jonathan D ^a,b   Goodwin, James S ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HEALTH SURVEY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; UNITED STATES;

EID: 0037458216     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-2-200301210-00009     Document Type: Article

References (47)

1. Consensus conference. Adjuvant chemotherapy for breast cancer. JAMA. 1985;254:3461-3. [PMID: 4068189]
2. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1988;319:1681-92. [PMID: 3205265]
3. NIH consensus conference. Treatment of early-stage breast cancer. JAMA. 1991;265:391-5. [PMID: 1984541]
4. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992;339:1-15. [PMID: 1345950]
5. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89:1673-82. [PMID: 9390536]
6. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;352:930-42. [PMID: 9752815]
7. Adjuvant systemic therapy for women with node-negative breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ. 1998;158 Suppl 3:S43-S51. [PMID: 9484278]
8. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ. 1998;158 Suppl 3:S52-S64. [PMID: 9484279]
9. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974-84. [PMID: 9753714]
10. Fisher B. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA Cancer J Clin. 1999;49:159-77. [PMID: 10445015]
11. Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, et al. NCCN Practice Guidelines for Breast Cancer. Oncology (Huntingt). 2000;14:33-49. [PMID: 11195418]
12. Eifel P, Axelson JA, Costa J, Crowley J, Curtan WJ Jr, Deshler A, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001;93:979-89. [PMID: 11438563]
13. Chu J, Diehr P, Feigl P, Glaefke G, Begg C, Glicksman A, et al. The effect of age on the care of women with breast cancer in community hospitals. J Gerontol. 1987;42:185-90. [PMID: 3819344]
14. Osteen RT, Cady B, Chmiel JS, Clive RE, Doggett RL, Friedman MA, et al. 1991 national survey of carcinoma of the breast by the Commission on Cancer. J Am Coll Surg. 1994;178:213-9. [PMID: 8149010]
15. Wilson RE, Donegan WL, Mettlin C, Natarajan N, Smart CR, Murphy GP. The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons. Surg Gynecol Obstet. 1984;159:309-18. [PMID: 6484787]
16. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19:1455-61. [PMID: 11230491]
17. Du X, Goodwin JS. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer. 2001;92;730-7. [PMID: 11550141]
18. Ries LA, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK, eds. SEER Cancer Statistics Review, 1973-1994. Bethesda, MD: National Cancer Institute; 1997. NIH publication no. 97-2789.
19. The New Mexico Tumor Registry. About the New Mexico Tumor Registry. Accessed at http://hsc.unm.edu/epiccpro/nmtr.html on 18 November 2002.
20. The SEER Program Code Manual. Revised ed. Bethesda, MD: National Cancer Institute; 1994. NIH publication no. 94-1999.
21. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. Cary, NC: SAS Institute; 1997.
22. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: J Wiley; 2000:17-21.
23. Greenland S. Basic methods for sensitivity analysis and external adjustment. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven; 1998:343-57.
24. Mann BA, Samet JM, Hunt WC, Key CR, Goodwin JM, Goodwin JS. Changing treatment of breast cancer in New Mexico from 1969 through 1985. JAMA. 1988;259:3413-7. [PMID: 3373679]
25. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS. Choice of cancer therapy varies with age of patient. JAMA. 1986;255:3385-90. [PMID: 3712698]
26. Lazovich DA, White E, Thomas DB, Moe RE. Underutilization of breast-conserving surgery and radiation therapy among women with stage I or II breast cancer. JAMA. 1991;266:3433-8. [PMID: 1688350]
27. Goodwin JS, Samet JM, Hunt WC. Determinants of survival in older cancer patients. J Natl Cancer Inst. 1996;88:1031-8. [PMID: 8683633]
28. Du XL, Freeman JL, Freeman DH, Syblik DA, Goodwin JS. Temporal and regional variation in the use of breast-conserving surgery and radiotherapy for older women with early-stage breast cancer from 1983 to 1995. J Gerontol A Biol Sci Med Sci. 1999;54:M474-8. [PMID: 10536651]
29. Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst. 2000;92:269-71. [PMID: 10655446]
30. Du X, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology and End Results. J Clin Epidemiol. 1999;52:463-70. [PMID: 10360342]
31. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS. Choice of cancer therapy varies with age of patient. JAMA. 1986;255:3385-90. [PMID: 3712698]
32. Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA. 1987;257:2766-70. [PMID: 3573271]
33. Wetle T. Age as a risk factor for inadequate treatment [Editorial]. JAMA. 1987;258:516. [PMID: 3599351]
34. Goodwin JS, Hunt WC, Humble CG, Key CR, Samet JM. Cancer treatment protocols. Who gets chosen? Arch Intern Med. 1988;148:2258-60. [PMID: 3178383]
35. Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer. 1993;72:594-601. [PMID: 8319193]
36. Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001;62-6. [PMID: 11773294]
37. Muss HB. The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women. Cancer. 1994;74:2165-71. [PMID: 8087784]
38. Muss HB. Chemotherapy of breast cancer in the older patient. Semin Oncol. 1995;22:14-6. [PMID: 7863346]
39. Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]. JAMA. 1992;268:57-62. [PMID: 1608114]
40. Nerenz DR, Love RR, Leventhal H, Easterling DV. Psychosocial consequences of cancer chemotherapy for elderly patients. Health Serv Res. 1986;20:961-76. [PMID: 3949543]
41. Du XL, Osborne C, Goodwin JS. Population-Based Assessment of Hospitalizations for Toxicity from Chemotherapy in Older Women with Breast Cancer. J Clin Oncol. 2002;20:4636-42.
42. Shekelle PG, Ortiz E, Rhodes S, Morton SC, Eccles MP, Grimshaw JM, et al. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? JAMA. 2001;286:1461-7. [PMID: 11572738]
43. Field MJ, Lohr KN. Guidelines for Clinical Practice: From Development to Use. Washington, DC: National Academy Pr; 1992.
44. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527-30. [PMID: 10024268]
45. Shekelle P, Eccles MP, Grimshaw JM, Woolf SH. When should clinical guidelines be updated? BMJ. 2001;323:155-7. [PMID: 11463690]
46. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Under-representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-7. [PMID: 10615079]
47. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-48. [PMID: 8336512].